Natera (NTRA) Stock Price, News & Analysis

Company Overview

Natera, Inc. is a diagnostics company that develops and commercializes molecular testing services designed to assess genetic and disease-related risks. The company uses technologies including cell-free DNA analysis and next-generation sequencing to support clinical decision-making in reproductive health, oncology and organ transplantation.

Its reproductive health offerings include Panorama, a noninvasive prenatal test that screens for certain chromosomal conditions, and Horizon, a carrier screening test that evaluates whether prospective parents carry genetic variants associated with inherited disorders. Natera also offers testing related to fertility and pregnancy management.

In oncology, the company’s Signatera test is designed to detect and monitor minimal residual disease and molecular recurrence using personalized, tumor-informed assays. Its transplant portfolio includes Prospera, which analyzes donor-derived cell-free DNA to help monitor for potential organ rejection. Natera was founded in 2004 and is headquartered in Austin, Texas. The company serves healthcare providers and patients in the United States and select international markets and is led by Chief Executive Officer Steve Chapman.

Key Stats

• Today's Range: $384.23 to $408.82
• 50-Day Range: $309.93 to $425.64
• 52-Week Range: $178.01 to $437.41
• Volume: 1.21 million shs
• Average Volume: 1.93 million shs
• Market Capitalization: $58.35 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $368.69
• Consensus Rating: Moderate Buy

Natera Stock Analysis - MarketRank™

Natera scored higher than 39% of companies evaluated by MarketBeat, and ranked 711th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Natera has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 2 strong buy ratings, 16 buy ratings, 4 hold ratings, and 1 sell rating.

Downside Risk

Natera has a consensus price target of $368.69, representing about 8.9% downside from its current price of $404.79.

Amount of Analyst Coverage

Natera has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Natera are expected to grow in the coming year, from ($1.02) to $0.01 per share.

Price to Book Value per Share Ratio

Natera has a P/B Ratio of 32.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.64% of the float of Natera has been sold short.

Short Interest Ratio / Days to Cover

Natera has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Natera has recently increased by 32.48%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Natera does not currently pay a dividend.

Dividend Growth

Natera does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.65

News Sentiment

Natera has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Natera this week, compared to 10 articles on an average week.

Search Interest

37 people have searched for NTRA on MarketBeat in the last 30 days. This is an increase of 118% compared to the previous 30 days.

MarketBeat Follows

Only 8 people have added Natera to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Natera insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,119,137.00 in company stock.

Percentage Held by Insiders

5.05% of the stock of Natera is held by insiders.

Percentage Held by Institutions

99.90% of the stock of Natera is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/15/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:NTRA
• CIK: 1604821
• Web: www.natera.com
• Phone: (650) 249-9090
• Fax: N/A
• Employees: 6,140
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Natera: $368.69
• High Price Target: $480.00
• Low Price Target: $172.00
• Potential Upside/Downside: -8.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 23 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.36)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$208.16 million
• Net Margins: -7.11%
• Pretax Margin: -9.33%
• Return on Equity: -11.38%
• Return on Assets: -7.87%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.00
• Quick Ratio: 2.85

Sales & Book Value

• Annual Sales: $2.31 billion
• Price / Sales: 25.30
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $12.38 per share
• Price / Book: 32.70

Miscellaneous

• Outstanding Shares: 144,140,000
• Free Float: 136,865,000
• Market Cap: $58.35 billion
• Optionable: Optionable
• Beta: 1.50